Susceptibility of Helicobacter pylori to simethicone and other non-antibiotic drugs | Zendy

R. Ansorg | Zendy; G. von Recklinghausen | Zendy; Evelyn Heintschel von Heinegg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Susceptibility of Helicobacter pylori to simethicone and other non-antibiotic drugs

Author(s) -

R. Ansorg,

G. von Recklinghausen,

Evelyn Heintschel von Heinegg

Publication year - 1996

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/37.1.45

Subject(s) - ketoconazole , allopurinol , helicobacter pylori , antibiotics , pharmacology , antibacterial agent , microbiology and biotechnology , chemistry , biology , medicine , antifungal

The antifoaming agent simethicone (Lefax), the protease inhibitor gabexate mesilate (FOY), the antimycotic ketoconazole, and the hydroxyl scavangers dimethylsulphoxide (DMSO) and allopurinol were investigated for growth inhibition of Helicobacter pylori and representative strains of other bacterial species. H. pylori were selectively inhibited by 64-128 mg/L of simethicone, 64-128 mg/L gabexate mesilate, and 16-64 mg/L ketoconazole. Dimethylsulphoxide and allopurinol showed no antibacterial effect at concentrations used therapeutically. It is concluded that gabexate mesilate, ketoconazole and, particularly, simethicone are candidates for treatment of H. pylori infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research